Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.59
+0.17 (11.97%)
After Hours: 1.63 +0.04 (2.52%)
May 27, 7:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.48 - 1.65
52 week 1.27 - 3.58
Open 1.51
Vol / Avg. 13.88M/2.44M
Mkt cap 234.07M
P/E     -
Div/yield     -
EPS -0.36
Shares 161.72M
Beta 1.35
Inst. own 20%
Aug 10, 2015
Q2 2015 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 19, 2015
Galena Biopharma Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Galena Biopharma Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Galena Biopharma Inc Earnings Release
Apr 14, 2015
Galena Biopharma Inc at Needham Healthcare Conference
Mar 24, 2015
Galena Biopharma Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 9, 2015
Galena Biopharma Inc at ROTH Conference
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Call - Webcast
Mar 5, 2015
Q4 2014 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -383.16% -392.81%
Operating margin -416.25% -558.56%
EBITD margin - -550.84%
Return on average assets -44.70% -43.46%
Return on average equity -87.92% -170.48%
Employees 57 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is focused on developing and commercializing oncology therapeutics that address medical needs across a spectrum of cancer care. Galena’s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company’s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. It also offers peptide immunotherapy product candidate, GALE-301 (Folate Binding Protein), an immunogenic peptide combined with rhGM-CSF that can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy Folate Binding Protein (FBP) expressing cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap CPA Chief Financial Officer, Vice President, Secretary
Age: 45
Bio & Compensation  - Reuters
Margaret A. Kivinski Esq. Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 73
Bio & Compensation  - Reuters